Zobrazit v EDS

Cancer risks of hematopoietic/lymphatic and urinary system in pharmaceutical plant workers: a systematic review and meta-analysis

Uloženo v:
Podrobná bibliografie
Název: Cancer risks of hematopoietic/lymphatic and urinary system in pharmaceutical plant workers: a systematic review and meta-analysis
Autoři: Jinyoung Moon, Yongseok Mun
Zdroj: BMC Public Health, Vol 25, Iss 1, Pp 1-15 (2025)
Informace o vydavateli: BMC, 2025.
Rok vydání: 2025
Sbírka: LCC:Public aspects of medicine
Témata: Pharmaceutical plant workers, Cancer incidence, Cancer mortality, Hematopoietic system, Lymphatic system, Urinary system, Public aspects of medicine, RA1-1270
Popis: Abstract Introduction In this study, we will investigate the risk of hematopoietic/lymphatic system and urinary system cancers in pharmaceutical plant workers. Methods Six pre-defined inclusion criteria were applied. The quality of all included studies was assessed based on the National Toxicology Program Office of Health Assessment and Translation Risk of Bias tool. Conventional meta-analysis was conducted for hematopoietic/lymphatic system and urinary system cancers. Between-study heterogeneity and publication bias were investigated. Results In this systematic review and meta-analysis, four cohort studies of a single pharmaceutical plant, one case-control study, and one cohort study with a nested case-control study were included. For publication bias, the p-value for Egger’s regression test was 0.51 and 0.38 for hematopoietic/lymphatic and urinary system cancer, respectively. Pharmaceutical plant workers showed a 3.19 (95% confidence interval, CI 1.53–6.64) times higher risk of hematopoietic/lymphatic system cancers than the general population. They also showed a 4.86 (95% CI 1.71–13.80) times higher risk of urinary system cancers compared to the general population. Higgins’ I-squared value for between-study heterogeneity was 61.77% (95% CI 0.00–99.06%) and 58.00% (95% CI 0.00–98.67%), respectively. Conclusion From this systematic review and meta-analysis, the authors concluded that potential hazardous occupational exposures of workers in pharmaceutical plants could pose an increased risk of hematopoietic/lymphatic system and urinary system cancer. Future studies should be conducted with a more thorough dose-response relationship distinction.
Druh dokumentu: article
Popis souboru: electronic resource
Jazyk: English
ISSN: 1471-2458
Relation: https://doaj.org/toc/1471-2458
DOI: 10.1186/s12889-025-24408-2
Přístupová URL adresa: https://doaj.org/article/aad0c69b607a47b2bb12efe4b68aecd6
Přístupové číslo: edsdoj.0c69b607a47b2bb12efe4b68aecd6
Databáze: Directory of Open Access Journals
Popis
Abstrakt:Abstract Introduction In this study, we will investigate the risk of hematopoietic/lymphatic system and urinary system cancers in pharmaceutical plant workers. Methods Six pre-defined inclusion criteria were applied. The quality of all included studies was assessed based on the National Toxicology Program Office of Health Assessment and Translation Risk of Bias tool. Conventional meta-analysis was conducted for hematopoietic/lymphatic system and urinary system cancers. Between-study heterogeneity and publication bias were investigated. Results In this systematic review and meta-analysis, four cohort studies of a single pharmaceutical plant, one case-control study, and one cohort study with a nested case-control study were included. For publication bias, the p-value for Egger’s regression test was 0.51 and 0.38 for hematopoietic/lymphatic and urinary system cancer, respectively. Pharmaceutical plant workers showed a 3.19 (95% confidence interval, CI 1.53–6.64) times higher risk of hematopoietic/lymphatic system cancers than the general population. They also showed a 4.86 (95% CI 1.71–13.80) times higher risk of urinary system cancers compared to the general population. Higgins’ I-squared value for between-study heterogeneity was 61.77% (95% CI 0.00–99.06%) and 58.00% (95% CI 0.00–98.67%), respectively. Conclusion From this systematic review and meta-analysis, the authors concluded that potential hazardous occupational exposures of workers in pharmaceutical plants could pose an increased risk of hematopoietic/lymphatic system and urinary system cancer. Future studies should be conducted with a more thorough dose-response relationship distinction.
ISSN:14712458
DOI:10.1186/s12889-025-24408-2